University of Dundee - Confidence in Concept 2014

Lead Research Organisation: University of Dundee
Department Name: UNLISTED


Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.



Description European Lead Factory
Amount £500,000 (GBP)
Organisation European Commission 
Department Innovative Medicines Initiative (IMI)
Sector Public
Country Belgium
Start 06/2017 
Description High growth spinout
Amount £131,000 (GBP)
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 09/2020 
End 03/2021
Description MRC
Amount £823,000 (GBP)
Funding ID MR/P000509/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Description project grant
Amount £209,048 (GBP)
Organisation Versus Arthritis 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2014 
End 12/2016
Description project grant
Amount £261,067 (GBP)
Organisation Arch Therapeutics 
Sector Private
Country United States
Start 01/2017 
End 12/2019
Description translational medical research fund 2014
Amount £18,500 (GBP)
Organisation University of Dundee 
Sector Academic/University
Country United Kingdom
Start 04/2014 
Description Hit TB TbCoABC sub-project 
Organisation Foundation for the National Institutes of Health (FNIH)
Country United States 
Sector Charity/Non Profit 
PI Contribution Data and assays generated by the CiC supported HTS project. The hit Tb grant (our funded resource from the collaboration) we will support 1 FTE years chemistry and computational chemistry plus purchasing of commercial analogues of the hits.
Collaborator Contribution Structural biology Tb cell biology and animal model work on selected examples. Fragment screening data and assays.
Impact To early to generate defined outputs
Start Year 2015
Description Investment Partnership Agreement 
Organisation Perceptive Bioscience Holdings Ltd
Country United Kingdom 
Sector Academic/University 
PI Contribution The University has signed an Investment Partnership Agreement with Perceptive that will allow the DDU to further translate programmes developed with MRC CiC funding up to preclinical candidates.
Collaborator Contribution Perceptive will underwrite the CURE Fund for up to 10 years.
Impact The investment sum will be disclosed later in the year.
Start Year 2016
Company Name HepaRegeniX GmbH 
Description HepaRegeniX is a biopharmaceutical company focused on the discovery, development and clinical testing of selective and potent MKK4 inhibitors for liver disease and human tissue regeneration. The company, spun out of the University of Tubingen, was registered in January 2016 and has signed a collaboration with the DDU in Dundee where we have developed an screening assay for MKK4 and completed a diversity screen. The group in Germany was introduced to us through Boehringer Ingelheim Venture Fund who were looking for Dundee input to the technology before they committed to funding a spinout. 
Year Established 2016 
Impact Heparegenix currently only has a handfull of employees but is expected to have 20 by the year end when full funding has been secured. Dundee will be awarded £154,000 to acquire sole ownership of the Dundee MKK4 data.